Female sexual dysfunction in androgenetic alopecia: Case-control study

Basit Öğe Kaydı
dc.contributor.authorSancak, Eyup Burak
dc.contributor.authorOguz, Sevilay
dc.contributor.authorAkbulut, Tugba
dc.contributor.authorUludag, Aysegul
dc.contributor.authorAkbas, Alpaslan
dc.contributor.authorKurt, Omer
dc.contributor.authorAkbulut, Mehmet Fatih
dc.date.accessioned2025-01-27T20:45:34Z
dc.date.available2025-01-27T20:45:34Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: We sought to evaluate the association of female sexual dysfunction (FSD) with androgenetic alopecia (AGA) and metabolic syndrome (MetS) in premenopausal women. Methods: From December 2013 to June 2015, we performed a case-control, prospective study of 115 patients with AGA and 97 age-matched control patients without AGA from among premenopausal women who visited dermatology clinics of the two reference hospitals. Comprehensive history, anthropometric measurements, and questionnaire administration were performed for each of the total of 212 women. The Female Sexual Function Index (FSFI) was used to assess the key dimensions of female sexual function. AGA was assessed and graded by an experienced dermatologist according to Ludwig's classification. The MetS assessment was made according to the NCEP-ATP III criteria. Results: In univariate analysis, age, weight, waist circumference, hip circumference, waist-to-hip ratio, body mass index (BMI), AGA, MetS, cardiovascular event, marital status, hypertension, high fasting plasma glucose, high triglyceride, large waist, total testosterone, and free testosterone were associated with presence of FSD. In logistic regression analysis, age (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13. 1.30; p<0.001), AGA (OR 3.42, 95% CI 1.31. 8.94; p= 0.017), MetS (OR 5.39, 95% CI 1.34. 21.62; p= 0.012), and free testosterone (OR 0.18, 95% CI 0.09. 0.37; p< 0.001) were independently associated with FSD. Conclusions: Our study suggests that age, AGA, MetS, and free testosterone may have strong impact on sexual function in premenopausal women. Further studies with population-based and longitudinal design should be conducted to confirm this finding.
dc.identifier.doi10.5489/cuaj.3582
dc.identifier.endpageE256
dc.identifier.issn1911-6470
dc.identifier.issn1920-1214
dc.identifier.issue7-8
dc.identifier.pmid28255417
dc.identifier.scopus2-s2.0-84978173620
dc.identifier.scopusqualityQ3
dc.identifier.startpageE251
dc.identifier.urihttps://doi.org/10.5489/cuaj.3582
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24633
dc.identifier.volume10
dc.identifier.wosWOS:000382528100008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCanadian Urological Association
dc.relation.ispartofCuaj-Canadian Urological Association Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectMiddle-Aged Women
dc.subjectMetabolic Syndrome
dc.subjectInsulin-Resistance
dc.subjectRisk-Factors
dc.subjectIndex Fsfi
dc.subjectTestosterone
dc.subjectPrevalence
dc.subjectAssociation
dc.subjectTherapy
dc.subjectMen
dc.titleFemale sexual dysfunction in androgenetic alopecia: Case-control study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu